10 Best Pharma Stocks to Buy According to Billionaires

5. Zoetis Inc. (NYSE:ZTS)

Number of Billionaire Holdings: 15 

Zoetis Inc. (NYSE:ZTS) continues to strengthen its position as a global leader in animal health, with steady growth and expanding innovation. The company develops medicines, vaccines, and diagnostics for both livestock and companion animals, and its diverse product portfolio has driven consistent revenue gains of about 4.2% year over year. The corporation’s financial resilience is underscored by a strong return on equity above 55%, free cash flow exceeding $2.2 billion, and a dividend yield of roughly 1.3%, supported by a conservative payout ratio.

A key development for Zoetis Inc. (NYSE:ZTS) is its collaboration with Blacksmith Medicines to advance new antibiotics aimed at combating antimicrobial resistance in veterinary care, positioning the company at the forefront of a growing global challenge. At the same time, Zoetis is expanding in the companion animal market with innovative treatments. In September 2025, its arthritis therapy for cats, Portela (relfovetmab), received a positive opinion from the European Medicines Agency, reflecting the business’s commitment to addressing unmet needs in pet health.

Financially, Zoetis Inc. (NYSE:ZTS) has outperformed expectations, posting quarterly earnings per share of $1.76, above the $1.62 estimate, and setting full-year guidance at $6.30–$6.40.